Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to utilize neurophysiologic assessments, behavioral measures and clinical measures to assess how much deficits associated with Fragile X Syndrome from pre-dose to post-dose Acamprosate, lovastatin, minocycline and placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02998151
Study type Interventional
Source Children's Hospital Medical Center, Cincinnati
Contact
Status Enrolling by invitation
Phase Phase 2
Start date January 2016
Completion date July 2021

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT00965432 - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 Phase 1
Completed NCT01120626 - Randomized Controlled Study of Donepezil in Fragile X Syndrome Phase 2
Completed NCT01204151 - Teaching Math Skills to Individuals With Fragile X Syndrome N/A
Active, not recruiting NCT00334971 - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women N/A
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT03722290 - Metformin in Children and Adults With Fragile X Syndrome Phase 2
Recruiting NCT04141163 - Metformin in Patients With Fragile X Phase 1/Phase 2
Completed NCT00858689 - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Enrolling by invitation NCT03802799 - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Phase 2/Phase 3
Enrolling by invitation NCT03836300 - Pilot Study: A Parent-Infant Fragile X Intervention (PIXI) N/A
Completed NCT01725152 - Ganaxolone Treatment in Children With Fragile X Syndrome Phase 2
Terminated NCT01555333 - An Open Label Extension Study in Subjects With Fragile X Syndrome Phase 3
Terminated NCT01433354 - Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) Phase 2/Phase 3
Completed NCT01253629 - Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome Phase 2
Terminated NCT01013480 - An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome Phase 2
Completed NCT01015430 - A Study With RO4917523 in Patients With Fragile X Syndrome Phase 2
Completed NCT00788073 - Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome Phase 2
Recruiting NCT02769949 - Pediatric Patients With Metabolic or Other Genetic Disorders